Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective
- 3 October 2002
- journal article
- review article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 29 (11) , 1030-1034
- https://doi.org/10.1046/j.1440-1681.2002.03767.x
Abstract
1. No neuroprotective drug has yet been shown to be effective in treating acute ischaemic stroke in the clinic, despite evidence of efficacy in animal models. 2. An academic/industry round‐table grou...Keywords
This publication has 30 references indexed in Scilit:
- NXY-059, a Free Radical–Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate SpeciesStroke, 2001
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Clomethiazole Acute Stroke Study (CLASS)Stroke, 1999
- Delayed Treatment With an Adenosine Kinase Inhibitor, GP683, Attenuates Infarct Size in Rats With Temporary Middle Cerebral Artery OcclusionStroke, 1998
- Clinical Experience With Excitatory Amino Acid Antagonist DrugsStroke, 1995
- Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats.Stroke, 1992
- Induced hypertension during restoration of flow after temporary middle cerebral artery occlusion in the rat: Effect on neuronal injury and edemaSurgical Neurology, 1991
- Animal models of stroke: are they relevant to human disease?Stroke, 1990
- Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke, 1989
- Cerebral blood flow and edema following carotid occlusion in the gerbil.Stroke, 1980